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X-ray crystallographic identification of a protein-binding site for
both all-trans- and 9-cis-retinoic acid
(epididymis/retinoic acid-binding protein)
MARCIA E. NEWCOMER*, R. STEVEN PAPPAS, AND DAVID E. ONG
Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232-0146
Communicated by William J. Darby, June 28, 1993
ABSTRACT The elucidation of how a protein-binding site
might specifically recognize both the all-trans and 9-cis isomers
of retinoic acid is of particular interest because of the recently
discovered binding specificities of the nuclear receptors for
retinoic acid. Two families ofnuclear receptors for retinoic acid
have been described, which are designated RAR (for retinoic
acid receptor) and RXR (for retinoid-X receptor). The RXR
family of receptors is specific for 9-cis-retinoic acid, whereas
the RAR-type receptor is activated by either 9-cis- or all-trans-
retinoic acid. During the x-ray structure determination of a
secreted epididymal retinoic acid-binding protein, with and
without retinoic acid, we observed an electron density for the
bound all-trans-retinoic acid that indicates the protein-bound
all-trans form of the vitamin/hormone adopts a horseshoe-like
conformation that resembles the structure of the 9-cis isomer
of the ligand. We detail here the experiments that indicate the
electron density is indeed due to all-trans-retinoic acid and that
protein can also bind the 9-cis isomer. This observation and the
fact that the same protein also binds the synthetic retinoid
(E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphtha-
lenyl)-l-propenyl]-benzoic acid (TTNPB), a retinoic acid ana-
log that activates RAR but does not activate RXR, suggest that
the mechanism by which this protein recognizes both 9-cis- and
all-trans-retinoic acids may be analogous to the mechanism
used by RAR. Three crystallographic structures of retinol-
binding proteins have been described. In each of these struc-
tures the retinol binds with the isoprene tail fully extended.
This report represents an x-ray crystallographic description of
a protein-bound retinoid conformer that adopts a nonextended
conformation, and we believe this observation is relevant to the
ligand specificities described for the retinoic acid receptors.
Retinoic acid is a modulator ofgene expression for which two
families ofnuclear receptors have been described. One family
[retinoic acid receptor (RAR) (1, 2)] binds both all-trans- and
9-cis-retinoic acid, whereas the second family [retinoid-X
receptor (RXR) (3)] appears specific for the 9-cis isomer (4,
5). Details of retinoid recognition by proteins are available
from the structures of three retinol-binding proteins, the
serum retinol-binding protein (6, 7) and the cellular retinol-
binding proteins types I and II (8, 9). In all three of these
structures the all-trans-retinol is bound with the isoprene tail
fully extended. These proteins do not bind 9-cis-retinol (10).
Exactly how a single binding site for retinoic acid can
accommodate both the 9-cis and all-trans isomers, yet still
maintain a high degree of specificity, is not known. In the
course of the x-ray structural determination of a retinoic
acid-binding protein from rat epididymis (E-RABP) in our
laboratory, we observed for crystals of the binding protein
complexed with retinoic acid an electron density in the
putative binding site that was inconsistent with an extended
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement"
in accordance with 18 U.S.C. §1734 solely to indicate this fact.
retinoid but was consistent with either 9-cis-retinoic acid or
an all-trans-retinoic acid molecule rotated about the C8-C9
bond, which then resembles 9-cis-retinoic acid (Fig. 1A).
This observation suggested that this binding site might ac-
commodate either isomer. Only all-trans-retinoic acid had
been examined (12, 13). But both all-trans- and 9-cis-retinoic
acid are found in epididymal extracts (14). Such an ability to
bind both 9-cis- and all-trans-retinoic acid would make the
binding protein from rat epididymis a possible model for the
retinoid-recognition site of RAR or provide an interesting
contrast once that structure is solved. Here we report that
E-RABP does indeed bind all-trans-retinoic acid in the ro-
tated configuration and can also bind the 9-cis isomer. In
addition, the retinoic acid analog (E)-4-[2-(5,6,7,8-
tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]-
benzoic acid (TTNPB, Fig. 1B), an activator of retinoic acid
receptor a (3), also binds well to the epididymal protein,
extending the possible similarities in retinoid-recognition
sites between these two proteins.t
MATERIALS AND METHODS
Protein Purification and Ligand-Binding Studies. Retinoic
acid-binding protein was purified as described (13). The
protein is expressed in two forms, B and C, which differ at the
amino-terminal end: the C form has an additional three amino
acids. Results are reported for the C form; experiments with
the B form gave equivalent results. The 9-cis isomer of
retinoic acid was prepared by oxidative esterification of
9-cis-retinal (15). All-trans- and 13-cis-retinoic acid were
purchased from Sigma. TTNPB was from M. Dawson (SRI
International, Menlo Park, CA). Stock solutions of 1:1 retin-
oic acid isomers and TTNPB were prepared in dimethyl
sulfoxide. The protein was incubated in Amicon Centricon-10
tubes with the retinoids in a 300-,l vol. Final incubation
conditions were 1% dimethyl sulfoxide/10 ,uM retinoic acid-
binding protein/20 ,M retinoid for each retinoid added. The
tubes were flushed with N2 and incubated at 21°C for 1 hr and
then incubated overnight at 4°C. To confirm that no signifi-
cant changes in isomer composition had occurred, a 100-j1
vol was withdrawn and extracted. The remaining 200 ,u was
diluted to 2.0 ml with phosphate-buffered saline and subse-
quently concentrated to 100 j4 by centrifugation. The dilution
and concentration was then repeated twice to remove un-
bound ligand. Control experiments with lysozyme confirmed
that the retinoic acid that remained in the retentate with
E-RABP was specifically bound. Ligand was extracted from
Abbreviations: RAR, retinoic acid receptor; RXR, retinoid-X recep-
tor; TTNPB, (E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-
naphthalenyl)-1-propenyl]-benzoic acid; E-RABP, epididymal retin-
oic acid-binding protein.
*To whom reprint requests should be addressed.
tThe atomic coordinates and structure factors have been deposited
in the Protein Data Bank, Chemistry Department, Brookhaven










































FIG. 1. (A) All-trans-retinoic acid from the coordinates of Stam
(11), a conformer of all-trans-retinoic acid that resembles 9-cis-
retinoic acid and 9-cis-retinoic acid. The all-trans conformer was
produced by rotation about the C8-C9 single bond. A rotation about
the C6-C7 single bond is also required to put the f-ionone ring in
the same relative position. (B) Structure of TTNPB.
the protein with 2.0 ml of hexane after the addition of 2 vol
of 0.05 M HCl/ethanol and 2 vol of 5 M NaCl to the protein
samples. Analysis by adsorption HPLC was done as de-
scribed (14).
Crystallization. Crystals of the holo-retinoic acid-binding
protein were prepared from the purified B form of the protein
to which a 20-fold excess of retinoic acid (dissolved in
dimethyl sulfoxide) was added in 0.1% lauryldimethylamine
oxide/10 mM Tris HCl, pH 8.0. Excess retinoic acid was
removed by passage over a C18 Sephadex column (13),
although this step was not necessary to produce crystals with
the reconstituted protein. Crystals grew in hanging-drop
vapor-diffusion experiments from ammonium sulfate concen-
trations of 31% saturated ammonium sulfate/10 mM
Tris HCl, pH 8.0/10-12% (wt/vol) glycerol/2.5 mM EDTA
at room temperature. These conditions resemble those for the
apoprotein crystallizations, except that 40% saturated am-
monium sulfate is used for apoprotein crystal growth. The
crystals grew (with or without seeding with apo-crystals) as
flat, thin, rectangular plates, a morphology quite distinct from
that of the apo-crystals. However, the crystals belong to the
same space group (P21) and are reasonably isomorphous with
the apo-crystals: a = 39.8, b = 58.9, c = 66.6, = 109.44°
(holo) vs. a = 39.3, b = 58.7, c = 66.3, 13 = 109.35° (apo).
There are two molecules of E-RABP per asymmetric unit.
X-Ray Data Collection and Map Calculation. X-ray data
were taken with a pair of San Diego Multiwire area detectors
mounted on a Rigaku RU-200 rotating anode. Rmerge for the
94% complete data set was 6.88% for 53,778 reflections
(14,116 unique). (Rmerge = 7:II - {I}I/IX{I}, where I = intensity
measurement for a given reflection and {I} is the mean
intensity for multiple measurements of the reflection.) The
difference Fourier calculation was done with partial-
structure phases (863 nonhydrogen atoms per monomer of a
possible 1282 total) combined with the multiple isomorphous
replacement phases (figure of merit after phase combination
= 0.68) and (Fholo - Fapo) amplitudes. The map is contoured
at two times the SD.
Structure Solution. The structure of the apo-retinoic acid-
binding protein was solved by the method of multiple isomor-
phous replacement to 2.1 A and will be reported elsewhere
(16). The coordinates for the apoprotein with those water
molecules not in the binding cavity were then used as the
starting model for the holo-protein, for which we had diffrac-
tion data to 2.2 A. The retinoic acid molecules were added, and
the side chains of Met-39 in the two crystallographically
independent protein molecules were positioned according to
the electron density in the difference Fourier calculation. The
structure was refined with the simulated annealing protocol of
XPLOR 2.1 (17). The residual error (R) value for the current
model is 18.2% for 94% of the data (those reflections with
intensities better than two times the SD) between 6- and 2.2-A
resolution. The low-resolution data were included in the
calculation of the 2Fo - Fcmaps (FO, observed structure factor
amplitudes; F,, calculated structure factor amplitudes). The
calculation of omit maps, also including the low-resolution
data, confirmed the placement of the retinoic acid molecules.
The electron density for the retinoic acid of the protein
molecule designated "A" was not as clear as that for "B" in
either the original difference Fourier calculations or the 2FO -
F, maps. The rms deviations from ideality for bond lengths and
angles are 0.017 A and 3.37°, respectively, for the current
model. Phasing, phase combination, and map calculation
before the use of XPLOR for refinement were done with the
PHASES package (W. Furey, Veterans Administration Medical
Center and University of Pittsburgh). For map interpretation
O version 5.6 was used (18).
Extraction of Retinoic Acid from the Crystal. The crystals
that were extracted had been in the hanging-drop experi-
ments at room temperature for over 18 mo. Crystals were
removed from the drops and washed with a large excess of
freshly prepared "mother liquor" to remove any retinoic
acid, or retinoic acid degradation products, which may have
been free in the drops. The mother liquor was then removed,
and the crystals were dissolved in water. All manipulations
with the crystal, until it was dissolved in water, were done
under a light microscope. The protein solution was extracted,
as described above, for the solution studies, and the retinoic
isomers were analyzed by HPLC (14).
RESULTS
To determine the x-ray crystallographic structure of
E-RABP, both with and without ligand, crystals of holo-
retinoic acid-binding protein were grown from reconstituted
retinoic acid-E-RABP as described above. The crystalliza-
tion of the apo form has been reported (13). The structure of
the bound ligand was determined by standard difference
Fourier methods: the structure of the apoprotein is "sub-
tracted," so that only the additional electron density of the
ligand, as well as that due to any conformational changes
induced by the addition of ligand, is visible in the electron
density map. The 3-ionone ring of the retinoic acid was
clearly visible in the difference Fourier calculated with the
multiple isomorphous replacement phases and amplitudes
derived from the holoprotein x-ray data. The ligand-binding
site of E-RABP was found deep within the 13barrel structure
of the protein. During the structural determination of the apo
form of E-RABP, the multiple isomorphous replacement
phases were improved by phase combination with those
calculated from partial-structure information (863 of 1282
atoms per monomer). In the difference Fourier value calcu-
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FIG. 2. A 2.4-A-resolution difference Fourier density. All-trans-
(yellow), 9-cis- (red), and folded all-trans- (lime) retinoic acid are fit
into the difference electron density. The other large density is due to
the side chain of Met-39 (magenta), which has moved into a position
different than that it adopts in the apo structure.
lated at this point (Fig. 2) the isoprene tail also became
visible. The isoprene tail was clearly not in the extended
all-trans conformation seen for that of the retinol in the x-ray
structures of the human serum retinol-binding protein and
cellular retinol-binding protein types I and II but was "bent"
in a horseshoe conformation.
It was not possible to distinguish from the difference
electron density whether the retinoic acid was the 9-cis
isomer or an all-trans-retinoic acid that has been twisted
about the C8-C9 bond, as illustrated in Fig. 1A. Indeed, the
crystal could contain either or both isomers. Although the
holoprotein was prepared by the addition of a solution of
all-trans-retinoic acid to the apoprotein, it was possible that
some isomerization occurred to produce 9-cis-retinoic acid,
which was then preferentially bound by E-RABP. Thus, it
was necessary to establish the nature of the bound ligand.
Holo-crystals, which were from the same crystallization
experiments as that crystal used for the x-ray data collection,
were extracted and analyzed for retinoic acid isomers by
HPLC (14). The presence of all-trans-retinoic acid was
confirmed, with some 9-cis and 13-cis isomer also present.
The ratio of all-trans-retinoic acid to the 9-cis isomer was
2.06/1.0 (Fig. 3). The presence of 13-cis isomer in the crystal
extract, despite the fact that it does not compete well with
all-trans-retinoic acid for binding to E-RABP (12), may be
due to the fact that the 13-cis isomer is an abundant product
of light isomerization of all-trans-retinoic acid (19). The
length of time required for the crystallization experiments
and the necessary periodic monitoring of the experiments
under a light microscope perhaps allowed significant amounts
of the 13-cis isomer to accumulate in the crystal.
The demonstration of all-trans-retinoic acid in the binding
site, confirming previous binding studies (12), then led us to
test the ability of E-RABP to bind 9-cis-retinoic acid and
compare the binding of the 9-cis isomer with that for the
all-trans isomer. We incubated E-RABP with mixtures of
all-trans-, 9-cis-, and 13-cis-retinoic acid. Protein-bound li-
gand was separated from free ligand and then extracted for
analysis. The relative abundance of the various isomers was
a
b
:1 3 5 7
time (miutes)
FIG. 3. Chromatogram of the retinoids extracted from holo-
crystals ofE-RABP. Peaks are observed at retention times indicative
of 13-cis- (a), 9-cis- (b), and all-trans- (c) retinoic acid.
quantitated by HPLC (Table 1). The 9-cis and all-trans
isomers of retinoic acid bound to E-RABP with almost equal
affinity. Affinity of the protein for the 13-cis isomer is
significantly lower, at least by a factor of 10, consistent with
previous competition studies (12). We also found that TT-
NPB, a synthetic retinoid that is 80% as active as all-trans-
retinoic acid in assays of the nuclear receptor RAR-a (3),
competed well with 9-cis- or all-trans-retinoic acid for binding
to E-RABP. Although conformationally restricted, rotation
about single bonds can position the carboxyl group and the
initial ring ofTTNPB in the same relative positions found for
9-cis- or all-trans-retinoic acid in the binding site. That
TTNPB does indeed adopt the same horseshoe conformation
has been confirmed with x-ray crystallographic studies of
TTNPB-soaked crystals of apo-E-RABP (J. Huntington and
M.E.N., unpublished observation).
The basic structural framework of E-RABP is an eight-
stranded up-and-down 3-sheet core that twists into a barrel
(Fig. 4). One end of the barrel is closed by amino acid side
chains in the barrel interior and amino acid side chains from
the amino terminus, which wraps across the back end of the
barrel. The front end of the barrel is open and provides
entrance to the binding site. The structural motif described
Table 1. Relative abundance of the retinoic acid isomers
recovered from E-RABP (C form)
Isomer, %
Ligands 13-cis 9-cis All-trans
All-trans, 9-cis 0 58 42
9-cis, 13-cis 10 90 0
All-trans, 13-cis 6 0 94
All-trans, TTNPB 0 0 58*
9-cis, TTNPB 0 64 0
Data are expressed as percentage of total retinoid recovered for
experiments with isomers of retinoic acid. When TTNPB was
present, recovery of retinoic acid isomers is expressed as percentage
recovered compared with recovery without TTNPB; TTNPB was
not quantitated.
*Ligands were provided in equimolar amounts.
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FIG. 4. Ribbon diagram of the C,,, backbone of E-RABP with
retinoic acid in the binding cavity.
for E-RABP was first described for the human serum retinol-
binding protein, a protein with which E-RABP shares slightly
<20% amino acid sequence identity (20). A detailed compar-
ison of the two proteins will be presented with the report of
the apoprotein structure (16).
In the inside of the ,-barrel is a large and deep cavity that
forms the retinoic acid-binding site and binding-site entrance.
The deepest part of the cavity is lined with hydrophobic
amino acids. Charged amino acids are found in the cavity
proximal to the binding-site entrance. The entrance itself,
formed by the inside faces of the two p-sheets, has both
hydrophobic and charged amino acids. The side chains that
line the binding cavity are Phe-6, Phe-11, Trp-15, Met-39,
Val-41, Leu-48, Leu-50, Phe-76, Val-78, Arg-80, Lys-85,
Val-87, Val-89, Ala-98, Ile-100, Ile-102, Lys-115, and Tyr-
117. The five aromatic amino acids, Phe-6, Phe-11, Trp-15,
Phe-76, and Tyr-117, are deepest in the binding cavity. They
form a semi-circle at the back end of the barrel, and the
,pionone ring of the retinoic acid is at the center of this
semicircle. More proximal to the entrance are Arg-80, Lys-
85, and Lys-115. The deepest ofthese residues is Lys-115, the
a-carbon ofwhich is located in the hydrophobic portion ofthe
binding site. The side chain ofLys-115 stretches out along the
"bottom" side of cavity toward the binding-site entrance so
that the positively charged amino group is at the entrance end
of the binding site, positioned to hydrogen bond with the
ligand carboxylate. Lys-85 is at the interface of the large
entrance to the site and the binding cavity itself and comes
from the "top" side of the cavity to hydrogen bond with the
retinoic acid carboxylate. The binding-site entrance is lined
with both hydrophobic and charged amino acids. His-111 and
Arg-80 come from the inside face of the "top" p-sheet, and
Glu-17 and Glu-63 come from the inside face ofthe "bottom"
p-sheet. If one tries to model 13-cis-retinoic acid in the
binding site, the carboxylate of the ligand is positioned
unfavorably close to Glu-17. This observation would explain
the reduced affinity of E-RABP for the 13-cis isomer.
The retinoic acid fits snugly into the hydrophobic pocket of
E-RABP, as the contours of the protein are complementary
to those of the hormone. The surface area of the bound
retinoic acid accessible to a solvent molecule is <30 A2,
compared to an area of 660 A2 for the free ligand. The
solvated portion of the retinoic acid corresponds to the
carboxylate region. To illustrate complementarity ofthe fit of
the ligand in the protein-binding site we have calculated the
accessible surface area of the holoprotein without ligand and
the accessible surface areas of 9-cis and all-trans (in the
conformer observed in the protein-binding site)-retinoic acid.
In Fig. 5 we have taken cross sections of the surface
representation of E-RABP, so that the internal contours of
the binding site are visible. In Fig. 5A, calculated for holo-
protein without ligand, one can see the deep binding cavity.




FIG. 5. Cross sections of the surface representations ofE-RABP
in which the binding cavity is visible. Dots mark the surfaces
accessible to solvent molecules. The figures were generated with
Biosym software that incorporates the algorithm of Connolly (21). A
solvent probe radius of 1.6 A was used with the coordinates for all
nonhydrogen atoms. (A) Holo-E-RABP without retinoic acid (ste-
reo). (B) Holo-E-RABP as in A but with the surface of all-trans-
retinoic acid mapped in darker dots. (C) Holo-E-RABP as in A but
with the surface of 9-cis-retinoic acid mapped in darker dots.
all-trans- and 9-cis-retinoic acid, respectively, into the bind-
ing cavity of the holoprotein (as shown in Fig. 5A). These
latter two representations, in addition to illustrating the
complementarity ofthe surfaces ofbinding cavity and ligand,
suggest that the binding site of E-RABP may be able to
recognize both 9-cis and all-trans isomers of retinoic acid
because the site can accommodate the isoprene methyl
groups in two different conformations.
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DISCUSSION
The isomer specificity of E-RABP that was predicted by the
shape of the electron density of the ligand in an x-ray
crystallographic study was confirmed experimentally. The
"folding" of the all-trans-retinoic acid isoprene tail suggests
a mechanism by which the same protein-binding site can
recognize both all-trans- and 9-cis-retinoic acid while main-
taining many of the same protein-ligand contacts. A folded
all-trans and 9-cis-retinoic acid can be superimposed so that
the shapes of the volumes occupied by the two structures are
roughly the same, as illustrated in Fig. 5 B and C. To make
the all-trans-retinoic acid most resemble the 9-cis isomer a
rotation about C6-C7 and C8-C9 is necessary. In the
variety of crystal structures of retinoids available, the /3io-
none ring has been seen to be in either ofthese conformations
(e.g., ref. 11). In the various crystallographic structures of
all-trans-retinoids reported, the isoprene tail is invariably in
the extended conformation. In addition, in the three struc-
tures of retinol-binding proteins determined, the isoprene tail
was found in the extended conformation. These x-ray struc-
tures include the human serum retinol-binding protein, which
has the same structural motif as E-RABP. In contrast to
E-RABP, human serum retinol-binding protein does not
discriminate between retinol and retinoic acid. The ligand
binding site of this retinol-binding protein resembles that for
E-RABP in that the retinol fits snugly in the binding cavity;
however, in E-RABP the retinoic acid is placed much deeper
into the ,3-barrel, and the ligand carboxylate interacts with
amino acid side chains on the inside of the 3-barrel. The
retinol-binding sites of the intracellular retinol-binding pro-
teins CRBP and CRBPII are also sandwiched between two
layers of 13-sheets. However, in these proteins, which have
their own common structural motif, the tail end, rather than
the ,B-ionone ring, is deepest in the barrel, and the internal
binding cavity does not conform extensively to the shape of
the ligand due to the presence of multiple water molecules in
the binding cavity.
We see here that upon binding to E-RABP, retinoic acid
adopts a conformation in which the tail is now "folded"
instead of extended. For the retinoid to assume this confor-
mation, a transitory break in the conjugation across the
length of the isoprene tail must occur, but once the isoprene
tail adopts a "pseudo-cis" conformation, conjugation is
restored. In the binding of retinoic acid to E-RABP there is
also a conformational change in the protein. The side chain
of Met-39 must move to allow the ,B-ionone ring to enter the
innermost region of the deep and hydrophobic binding
pocket. The mechanism described here for retinoid recogni-
tion, which requires that the retinoid undergo a conforma-
tional change, could be the same type of mechanism utilized
by RAR-a so that it can respond to both the 9-cis and all-trans
isomers ofthe hormone. It remains to be confwrmed by further
crystallographic studies with the variety of retinoids that
activate RAR-a whether the binding site of E-RABP can
serve as a structural model for the receptor-recognition site.
Structural homology of catalytic sites has often been ob-
served in proteins with no overall structural homology. The
pocket is primarily hydrophobic in nature and sequence
identity between E-RABP and RAR is not a necessary
prerequisite for binding-site structural homology: a hydro-
phobic pocket with similar contours could be created by an
assortment ofhydrophobic side chains in the context ofother
structural motifs.
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